Sangamo Therapeutics Inc (NASDAQ:SGMO) shares, rose in value, with the stock price up by 2.94% to the previous day’s close as strong demand from buyers drove the stock to $0.52.
Actively observing the price movement in the last trading, the stock closed the session at $0.50. Referring to stock’s 52-week performance, its high was $1.78, and the low was $0.29. On the whole, SGMO has fluctuated by -17.11% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 45.88M, with a low estimate of 2M and a high estimate of 11.3M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 6.65M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SGMO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SGMO currently trading nearly -5.70% and -34.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.49, while the 7-day volatility ratio is showing 10.01% which for the 30-day chart, stands at 9.68%. Furthermore, Sangamo Therapeutics Inc (SGMO)’s beta value is 1.40, and its average true range (ATR) is 0.06.
A comparison of Sangamo Therapeutics Inc (SGMO) with its peers suggests the former has fared considerably weaker in the market. SGMO showed an intraday change of 2.94% in last session, and over the past year, it shrunk by -67.84%%.
Data on historical trading for Sangamo Therapeutics Inc (NASDAQ:SGMO) indicates that the trading volumes over the past 3 months, they’ve averaged 2.42 million. According to company’s latest data on outstanding shares, there are 203.67 million shares outstanding.
Nearly 10.07% of Sangamo Therapeutics Inc’s shares belong to company insiders and institutional investors own 46.37% of the company’s shares. The stock has fallen by -4.69% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SGMO stock heading into the next quarter.
